Related Experiment Video
Updated: Sep 30, 2026

A Murine Ommaya Xenograft Model to Study Direct-Targeted Therapy of Leptomeningeal Disease
Published on: January 29, 2021
Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma?
Raja B Khan1, Weiji Shi, Howard T Thaler
1Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
Abstract:
Systemic high-dose methotrexate (HD-MTX) is the most effective chemotherapeutic agent in the treatment of primary central nervous system lymphoma (PCNSL). Leptomeningeal involvement is common and intrathecal methotrexate (IT-MTX) is frequently used in combination with HD-MTX, but its benefits are not established. Using a case-controlled retrospective study, matching patients treated with HD-MTX with or without IT-MTX, we found no difference in survival, disease control, or neurotoxicity.
